IN2015DN01767A - - Google Patents

Info

Publication number
IN2015DN01767A
IN2015DN01767A IN1767DEN2015A IN2015DN01767A IN 2015DN01767 A IN2015DN01767 A IN 2015DN01767A IN 1767DEN2015 A IN1767DEN2015 A IN 1767DEN2015A IN 2015DN01767 A IN2015DN01767 A IN 2015DN01767A
Authority
IN
India
Prior art keywords
probnp
mortality
transplantation
subjects
prediction
Prior art date
Application number
Other languages
English (en)
Inventor
James V Snider
Robert W Gerwien
Sven Jacobson
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Publication of IN2015DN01767A publication Critical patent/IN2015DN01767A/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Primary Health Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
IN1767DEN2015 2012-08-21 2013-08-21 IN2015DN01767A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261691706P 2012-08-21 2012-08-21
PCT/US2013/056020 WO2014031764A1 (en) 2012-08-21 2013-08-21 Multimarker risk stratification

Publications (1)

Publication Number Publication Date
IN2015DN01767A true IN2015DN01767A (ru) 2015-05-29

Family

ID=50148799

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1767DEN2015 IN2015DN01767A (ru) 2012-08-21 2013-08-21

Country Status (12)

Country Link
US (4) US20140058743A1 (ru)
EP (1) EP2888687B1 (ru)
JP (3) JP6450679B2 (ru)
CN (2) CN111834009A (ru)
AU (3) AU2013305829A1 (ru)
CA (1) CA2882303A1 (ru)
HK (2) HK1208092A1 (ru)
IN (1) IN2015DN01767A (ru)
MX (2) MX2015002254A (ru)
RU (1) RU2015110054A (ru)
SG (2) SG10201608854TA (ru)
WO (1) WO2014031764A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
DK2336359T3 (en) 2002-05-09 2016-05-30 Brigham & Womens Hospital 1L1RL-1 as cardiovascular disease marker
ATE476657T1 (de) 2006-04-24 2010-08-15 Critical Care Diagnostics Inc Vorhersage von letalität und detektion von schweren erkrankungen
EP2482078B1 (en) 2006-05-01 2016-02-03 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
ES2443125T3 (es) 2008-04-18 2014-02-17 Critical Care Diagnostics, Inc. Predicción del riesgo a sufrir episodios cardíacos adversos graves
CN103154027B (zh) 2010-04-09 2016-06-29 重症监护诊断股份有限公司 可溶性人st-2抗体和分析法
JP6215713B2 (ja) 2011-03-17 2017-10-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド 有害臨床転帰のリスクを予測する方法
AU2012284039B2 (en) 2011-07-18 2017-03-30 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
MX357740B (es) 2012-05-18 2018-07-23 Critical Care Diagnostics Inc Métodos para determinar el pronóstico del tratamiento de un sujeto con un desfibrilador cardíaco implantado, un dispositivo de tratamiento de resincronización cardíaca o un dispositivo combinado de desfibrilador cardíaco implantado y de resincronización cardíaca.
RU2019107598A (ru) 2012-08-16 2019-03-28 Критикал Кэа Дайэгностикс, Инк. Способы прогнозирования риска развития гипертензии
RU2015110054A (ru) 2012-08-21 2016-10-10 Критикал Кэа Дайэгностикс, Инк. Мультимаркерная стратификация риска
CA2935958A1 (en) * 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
EP3341723B1 (en) * 2015-08-28 2021-07-21 McMaster University Method of determining risk of an adverse cardiac event
US20170220749A1 (en) * 2016-02-01 2017-08-03 MD Aware LLC Systems and methods for identifying and using medical calculators
BR112018071395A2 (pt) * 2016-04-18 2019-02-05 Centre Dinvestigation Clinique Plurithematique Pierre Drouin Inserm Chu De Nancy Inst Lorrain Du Coe métodos de identificação de pacientes, método de previsão do risco de progressão para lvh, método de diferenciação em pacientes, métodos de previsão se pacientes se encontram com risco de progressão para lvh e uso
US12014832B2 (en) * 2017-06-02 2024-06-18 University Of Florida Research Foundation, Incorporated Method and apparatus for prediction of complications after surgery
RU2677611C1 (ru) * 2018-04-16 2019-01-17 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ прогнозирования неблагоприятных сердечно-сосудистых событий в течение 12 месяцев у больных хронической сердечной недостаточностью с рецидивом стенокардии после реваскуляризации миокарда
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
WO2021084747A1 (ja) * 2019-11-01 2021-05-06 日本電気株式会社 リスク予測装置、リスク予測方法、及びコンピュータプログラム

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
JPH0731479Y2 (ja) 1989-06-02 1995-07-19 内橋エステック株式会社 温度ヒューズ
US5217899A (en) 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
JP2665850B2 (ja) 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
JP2732005B2 (ja) 1992-12-14 1998-03-25 眞一 富永 ヒトｓｔ２をコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
AU7235296A (en) 1996-08-23 1998-03-06 Human Genome Sciences, Inc. T1 receptor-like ligand ii
AU6181498A (en) 1997-02-28 1998-09-18 Human Genome Sciences, Inc. T1/st2-receptor ligand iii
ES2374621T3 (es) 1997-04-02 2012-02-20 The Brigham And Women's Hospital, Inc. Medios para evaluar el perfil de riesgo de un individuo de sufrir una enfermedad ateroesclerótica.
EP0988552B1 (en) 1997-06-10 2010-11-24 Lpath, Inc. Methods for early detection of heart disease
CA2304263C (en) 1997-09-11 2008-07-29 Shionogi & Co., Ltd. Immunoassay method for bnp
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
GB9827348D0 (en) 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
WO2000035473A2 (en) 1998-12-18 2000-06-22 Scios Inc. Methods for detection and use of differentially expressed genes in disease states
AU5309600A (en) 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
FR2795823B1 (fr) 1999-07-01 2001-11-23 Inst Nat Sante Rech Med Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
FR2807170B1 (fr) 2000-03-30 2002-06-28 Sipal Charniere elastique a frottement reduit
US20020115081A1 (en) 2000-08-22 2002-08-22 Lee Richard T. Diagnosis and treatment of cardiovascular conditions
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US6537221B2 (en) 2000-12-07 2003-03-25 Koninklijke Philips Electronics, N.V. Strain rate analysis in ultrasonic diagnostic images
FI20010019A (fi) 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
WO2002089657A2 (en) 2001-05-04 2002-11-14 Biosite, Inc. Diagnostic markers of acute coronary syndromes and methods of use thereof
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
DK2336359T3 (en) 2002-05-09 2016-05-30 Brigham & Womens Hospital 1L1RL-1 as cardiovascular disease marker
US8263325B2 (en) 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
WO2004056868A2 (en) 2002-12-19 2004-07-08 Endocube Sas Nf-hev compositions and methods of use
US20040133079A1 (en) 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
US20040220155A1 (en) 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20060257558A1 (en) 2003-10-31 2006-11-16 Hiroshi Nomura Plasma polymerization of atomically modified surfaces
EP2386659B1 (en) 2003-11-26 2014-01-15 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
ES2381551T3 (es) 2003-12-05 2012-05-29 The Cleveland Clinic Foundation Marcadores de riesgo para enfermedad cardiovascular
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja) 2004-03-31 2005-10-20 Akira Matsumori 心疾患の検査法
WO2006077265A1 (en) 2005-01-24 2006-07-27 F. Hoffmann-La Roche Ag The use of bnp-type peptides and anp-type peptides for assessing the risk of suffering from a cardiovascular complication as a consequence of volume overload
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
US20070021977A1 (en) 2005-07-19 2007-01-25 Witt Biomedical Corporation Automated system for capturing and archiving information to verify medical necessity of performing medical procedure
JP4820192B2 (ja) 2006-03-17 2011-11-24 一般財団法人化学及血清療法研究所 急性冠症候群でのａｄａｍｔｓ１３の測定と利用
ATE476657T1 (de) 2006-04-24 2010-08-15 Critical Care Diagnostics Inc Vorhersage von letalität und detektion von schweren erkrankungen
ATE517341T1 (de) 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
EP2482078B1 (en) * 2006-05-01 2016-02-03 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
US20100055683A1 (en) 2006-05-02 2010-03-04 Critical Care Diagnostics, Inc. Diagnosis of pulmonary and/or cardiovascular disease
US8147817B2 (en) 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
RU2312591C1 (ru) 2006-06-14 2007-12-20 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией
CA2554659A1 (en) * 2006-07-25 2006-11-24 1128971 Alberta Ltd. Hanger flange for hanging a tubular body in a well
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
EP2158330A2 (en) * 2007-05-11 2010-03-03 Tufts Medical Center Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
WO2009040133A1 (en) * 2007-09-26 2009-04-02 Universitätsklinikum Heidelberg Osteopontin as novel prognostic biomarker for heart failure
FR2923029B1 (fr) 2007-10-26 2009-11-20 Minima Lunettes de type sans entourage a branches filaires
WO2009075566A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
ES2443125T3 (es) 2008-04-18 2014-02-17 Critical Care Diagnostics, Inc. Predicción del riesgo a sufrir episodios cardíacos adversos graves
WO2010054810A1 (en) * 2008-11-11 2010-05-20 B.R.A.H.M.S Ag Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
WO2011000874A1 (en) * 2009-07-01 2011-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting cardiovascular mortality risk
EP2568294B1 (en) * 2009-11-13 2015-01-07 BG Medicine, Inc. Risk Factors and Prediction of Myocardial Infaraction
US8258456B2 (en) * 2009-11-27 2012-09-04 Himax Imaging, Inc. Image sensor
CN103154027B (zh) 2010-04-09 2016-06-29 重症监护诊断股份有限公司 可溶性人st-2抗体和分析法
RU2618437C2 (ru) * 2010-11-01 2017-05-03 Б.Р.А.Х.М.С Гмбх Оценка прогноза и риска пациентов с неспецифическими жалобами
RU2452394C1 (ru) 2010-11-09 2012-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
JP6215713B2 (ja) 2011-03-17 2017-10-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド 有害臨床転帰のリスクを予測する方法
AU2012284039B2 (en) 2011-07-18 2017-03-30 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
MX357740B (es) 2012-05-18 2018-07-23 Critical Care Diagnostics Inc Métodos para determinar el pronóstico del tratamiento de un sujeto con un desfibrilador cardíaco implantado, un dispositivo de tratamiento de resincronización cardíaca o un dispositivo combinado de desfibrilador cardíaco implantado y de resincronización cardíaca.
RU2019107598A (ru) 2012-08-16 2019-03-28 Критикал Кэа Дайэгностикс, Инк. Способы прогнозирования риска развития гипертензии
RU2015110054A (ru) 2012-08-21 2016-10-10 Критикал Кэа Дайэгностикс, Инк. Мультимаркерная стратификация риска
JP6178687B2 (ja) 2013-09-27 2017-08-09 富士機械工業株式会社 グラビア塗工装置
CA2935958A1 (en) 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
US9934249B2 (en) 2014-06-03 2018-04-03 Conduent Business Machines Services, Llc Systems and methods for context-aware and personalized access to visualizations of road events
USD800333S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800332S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
SG10201608854TA (en) 2016-12-29
AU2021202116A1 (en) 2021-05-06
US20190237197A1 (en) 2019-08-01
CA2882303A1 (en) 2014-02-27
JP2020034573A (ja) 2020-03-05
HK1212057A1 (en) 2016-06-03
JP2015532715A (ja) 2015-11-12
SG11201501271TA (en) 2015-03-30
US10303844B2 (en) 2019-05-28
EP2888687A1 (en) 2015-07-01
JP6902083B2 (ja) 2021-07-14
AU2013305829A1 (en) 2015-03-05
WO2014031764A1 (en) 2014-02-27
JP2019053086A (ja) 2019-04-04
EP2888687B1 (en) 2023-08-02
AU2019201709B2 (en) 2021-01-07
JP6621520B2 (ja) 2019-12-18
EP2888687A4 (en) 2016-04-13
AU2019201709A1 (en) 2019-04-04
MX2020009943A (es) 2020-10-16
CN111834009A (zh) 2020-10-27
US20140058743A1 (en) 2014-02-27
CN104737170A (zh) 2015-06-24
US20170169179A1 (en) 2017-06-15
JP6450679B2 (ja) 2019-01-09
US10741290B2 (en) 2020-08-11
RU2015110054A (ru) 2016-10-10
US20200335220A1 (en) 2020-10-22
MX2015002254A (es) 2015-05-08
HK1208092A1 (en) 2016-02-19

Similar Documents

Publication Publication Date Title
IN2015DN01767A (ru)
WO2009129454A3 (en) Predicting risk of major adverse cardiac events
EA201590027A1 (ru) Способы детекции заболеваний или состояний
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
EA201590994A1 (ru) Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
PH12014502436A1 (en) In vitro method for the diagnosis and surveillance of cancer
MX360479B (es) Anticuerpos contra microbioma, factores de estres y marcadores de mastocitos como marcadores de diagnostico para ibs.
IN2014DN07247A (ru)
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
WO2012122334A3 (en) Procollagen carboxy-terminal propeptides as a target and treatment for angiogenesis related diseases
WO2011085057A3 (en) Methods for detecting insulin autoantibody
FI20115367A0 (fi) Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja
WO2013167727A3 (en) Method for determining arthritis relapse risk
GB201114909D0 (en) Biomarkers for lysosomal storage disorders
WO2012122094A3 (en) Biomarkers of cardiac ischemia
BR112013017683A2 (pt) método de medir a concentração de um analito em uma solução aquosa
NZ720311A (en) Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
MX371426B (es) Metodo para la prediccion de la aparicion de sintomas extrapiramidales (sep) inducidos por un tratamiento con antipsicoticos.
FR3015047B1 (fr) Procede d'estimation de l'etat de sante d'une batterie
WO2013106851A3 (en) Syncollin, pancreatic triacylglycerol lipase, and other biomarkers for diabetes
PL408305A1 (pl) Zastosowanie ceramidu C16 (C16-Cer) jako biomarkera w predykcji porodu przedwczesnego
UA85502U (ru) Способ оценки прогноза течения хронической болезни почек на фоне хронического пиелонефрита с наличием артериальной гипертензии
UA81994U (ru) Способ прогнозирования развития нестабильной стенокардии у больных с сахарным диабетом 2 типа
RU2013105660A (ru) Способ прогнозирования стадии рассеянного склероза с учетом показателей биохимического статуса